Summarized intent-to-treat and as-treated analyses for patients who received high-dose vitamin A or placebo
| . | CI . | P value . | |
|---|---|---|---|
| Vitamin A . | Placebo . | ||
| Intent-to-treat analyses | |||
| Primary end point | |||
| Acute grade 1-4 GVHD at day +100 | 0.125 | 0.2 | .5 |
| Secondary end point | |||
| Acute grade 2-4 GVHD at day +180 | 0.025 | 0.125 | .09 |
| Steroid refractory acute GVHD at day +180 | 0.025 | 0.1 | .17 |
| Acute GI GVHD at day +180 | 0.025 | 0.125 | .09 |
| Chronic GVHD at 1 y | 0.05 | 0.15 | .02 |
| As-treated analyses | |||
| Primary end point | |||
| Acute grade 1-4 GVHD at day +100 | 0.08 | 0.20 | .27 |
| Secondary end points | |||
| Acute grade 2-4 GVHD at day +180 | 0 | 0.125 | .02 |
| Steroid refractory acute GVHD at day +180 | 0 | 0.1 | .049 |
| Acute GI GVHD at day +180 | 0 | 0.125 | .02 |
| Chronic GVHD at 1 y | 0.027 | 0.15 | .01 |
| . | CI . | P value . | |
|---|---|---|---|
| Vitamin A . | Placebo . | ||
| Intent-to-treat analyses | |||
| Primary end point | |||
| Acute grade 1-4 GVHD at day +100 | 0.125 | 0.2 | .5 |
| Secondary end point | |||
| Acute grade 2-4 GVHD at day +180 | 0.025 | 0.125 | .09 |
| Steroid refractory acute GVHD at day +180 | 0.025 | 0.1 | .17 |
| Acute GI GVHD at day +180 | 0.025 | 0.125 | .09 |
| Chronic GVHD at 1 y | 0.05 | 0.15 | .02 |
| As-treated analyses | |||
| Primary end point | |||
| Acute grade 1-4 GVHD at day +100 | 0.08 | 0.20 | .27 |
| Secondary end points | |||
| Acute grade 2-4 GVHD at day +180 | 0 | 0.125 | .02 |
| Steroid refractory acute GVHD at day +180 | 0 | 0.1 | .049 |
| Acute GI GVHD at day +180 | 0 | 0.125 | .02 |
| Chronic GVHD at 1 y | 0.027 | 0.15 | .01 |